Similarly, in colon, melanoma, lung, and breast cancer models, exosome-like nanovesicles derived from FAP-engineered tumor cells have been used as a vaccine that inhibits tumor growth by a cytotoxic T lymphocyte (CTL)-mediated immune response against both tumor cells and FAP+ CAFs [232]. The gene discussed is FAP; the disease is neoplasm.